Innoviva, Inc. is Director & 10% Owner at Armata Pharmaceuticals, Inc. (ARMP). They have made 6 open-market trades across 2 companies since 2020, most recently 2022-03-31.
6 open-market purchases totalling $163.3M since 2020, never a sale. Across 6 scored buys the stock is down 12.0% at ninety days, and 17.5 points behind the S&P over the same stretch.
6 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 33% | 50% | 17% |
| Avg Move | -4.0% | -8.7% | -12.0% |
| Alpha | -5.3% | -11.4% | -17.5% |
| Scored | 6 | 6 | 6 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ARMP | BUY | 2022-03-31 | 2022-04-01 | $5.00 | $26.9M | -8.7% | -19.5% | -30.5% |
| ETTX | BUY | 2021-05-03 | 2021-05-20 | $2.00 | $7.5M | -1.3% | +17.4% | +0.0% |
| ARMP | BUY | 2021-03-17 | 2021-03-17 | $3.25 | $27.9M | -23.0% | -34.9% | -33.5% |
| ETTX | BUY | 2020-09-01 | 2020-09-01 | $2.68 | $25.0M | +3.1% | -29.2% | -36.8% |
| ETTX | BUY | 2020-06-11 | 2020-06-12 | $2.50 | $31.7M | -1.0% | +3.0% | -1.0% |
| ARMP | BUY | 2020-03-27 | 2020-03-31 | $2.87 | $44.3M | +7.1% | +10.9% | +29.8% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.